Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real World, Open Label, Quality of Life Study
Phase of Trial: Phase III
Latest Information Update: 04 May 2019
Price : $35 *
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Registrational; Therapeutic Use
- Sponsors Aimmune Therapeutics
- 13 Dec 2018 Status changed from recruiting to discontinued.
- 06 Dec 2018 This trial has been Discontinued in Sweden.
- 10 Aug 2018 New trial record